Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam + Metronidazole in Japanese cIAI
NCT04927312Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2021
- Primary completion
- Sep 2022
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ceftazidime + avibactam in Intra-abdominal infection (IAI), sponsored by Pfizer. Primary endpoint: Clinical Response at Test of Cure (TOC) Visit. Started Oct 2021; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT04927312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927312.